• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

程序性细胞死亡、氧化还原失衡与癌症治疗

Programmed cell death, redox imbalance, and cancer therapeutics.

作者信息

Dai Xiaofeng, Wang Danjun, Zhang Jianying

机构信息

Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.

BGI College & Henan Institute of Medical and Pharmaceutical Sciences in Academy of Medical Science, Zhengzhou University, Zhengzhou, China.

出版信息

Apoptosis. 2021 Aug;26(7-8):385-414. doi: 10.1007/s10495-021-01682-0. Epub 2021 Jul 8.

DOI:10.1007/s10495-021-01682-0
PMID:34236569
Abstract

Cancer cells are disordered by nature and thus featured by higher internal redox level than healthy cells. Redox imbalance could trigger programmed cell death if exceeded a certain threshold, rendering therapeutic strategies relying on redox control a possible cancer management solution. Yet, various programmed cell death events have been consecutively discovered, complicating our understandings on their associations with redox imbalance and clinical implications especially therapeutic design. Thus, it is imperative to understand differences and similarities among programmed cell death events regarding their associations with redox imbalance for improved control over these events in malignant cells as well as appropriate design on therapeutic approaches relying on redox control. This review addresses these issues and concludes by bringing affront cold atmospheric plasma as an emerging redox controller with translational potential in clinics.

摘要

癌细胞本质上是无序的,因此其内部氧化还原水平高于健康细胞。如果超过一定阈值,氧化还原失衡可能引发程序性细胞死亡,这使得依赖氧化还原控制的治疗策略成为一种可能的癌症管理解决方案。然而,各种程序性细胞死亡事件相继被发现,这使我们对它们与氧化还原失衡的关联以及临床意义(尤其是治疗设计)的理解变得复杂。因此,必须了解程序性细胞死亡事件之间在与氧化还原失衡关联方面的异同,以便更好地控制恶性细胞中的这些事件,并合理设计依赖氧化还原控制的治疗方法。本综述探讨了这些问题,并最终提出冷大气等离子体作为一种新兴的氧化还原控制器,在临床上具有转化潜力。

相似文献

1
Programmed cell death, redox imbalance, and cancer therapeutics.程序性细胞死亡、氧化还原失衡与癌症治疗
Apoptosis. 2021 Aug;26(7-8):385-414. doi: 10.1007/s10495-021-01682-0. Epub 2021 Jul 8.
2
Redox imbalance and biochemical changes in cancer.癌症中的氧化还原失衡和生化变化。
Cancer Res. 2013 Oct 15;73(20):6118-23. doi: 10.1158/0008-5472.CAN-13-1117. Epub 2013 Jul 22.
3
Cold atmospheric plasma: redox homeostasis to treat cancers?冷大气等离子体:通过氧化还原稳态治疗癌症?
Trends Biotechnol. 2023 Jan;41(1):15-18. doi: 10.1016/j.tibtech.2022.07.007. Epub 2022 Aug 16.
4
Nanomaterials-Induced Redox Imbalance: Challenged and Opportunities for Nanomaterials in Cancer Therapy.纳米材料诱导的氧化还原失衡:纳米材料在癌症治疗中的挑战与机遇
Adv Sci (Weinh). 2024 Apr;11(16):e2308632. doi: 10.1002/advs.202308632. Epub 2024 Feb 21.
5
Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers.受体介导的氧化还原失衡:对抗侵袭性癌症的新兴临床途径。
Biomolecules. 2022 Dec 15;12(12):1880. doi: 10.3390/biom12121880.
6
The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance.马拉巴酮 A 在白血病和实体瘤细胞系中的化疗反应的可变性取决于氧化还原失衡的程度。
Phytomedicine. 2015 Jul 15;22(7-8):713-23. doi: 10.1016/j.phymed.2015.05.007. Epub 2015 May 29.
7
Redox-active and redox-silent compounds: synergistic therapeutics in cancer.氧化还原活性和氧化还原沉默化合物:癌症中的协同疗法
Curr Med Chem. 2015;22(5):552-68. doi: 10.2174/0929867321666140915142219.
8
The redox regulation of thiol dependent signaling pathways in cancer.癌症中硫醇依赖性信号通路的氧化还原调节
Curr Pharm Des. 2006;12(34):4427-43. doi: 10.2174/138161206779010549.
9
Redox regulation of programmed cell death in lymphocytes.淋巴细胞中程序性细胞死亡的氧化还原调节
Free Radic Res. 1995 May;22(5):389-97. doi: 10.3109/10715769509147548.
10
Redox-based regulation of apoptosis: S-glutathionylation as a regulatory mechanism to control cell death.基于氧化还原的细胞凋亡调控:S-谷胱甘肽化作为调控细胞死亡的机制。
Antioxid Redox Signal. 2012 Mar 15;16(6):496-505. doi: 10.1089/ars.2011.4281. Epub 2011 Dec 22.

引用本文的文献

1
Signature of leukemia stem cell death pattern predicts prognosis and therapeutic response of acute myeloid leukemia patients.白血病干细胞死亡模式的特征可预测急性髓系白血病患者的预后和治疗反应。
Sci Rep. 2025 Aug 27;15(1):31612. doi: 10.1038/s41598-025-17288-4.
2
Machine learning-based construction of a programmed cell death-related model reveals prognosis and immune infiltration in pancreatic adenocarcinoma patients.基于机器学习构建的程序性细胞死亡相关模型揭示胰腺腺癌患者的预后及免疫浸润情况。
Sci Rep. 2025 Jul 11;15(1):25156. doi: 10.1038/s41598-025-10847-9.
3
Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998-2024).

本文引用的文献

1
Association Between Caregiver-Oncologist Discordance in Patient's Life Expectancy Estimates and Caregiver Perceived Autonomy Support by the Oncologist.照顾者与肿瘤医生对患者预期寿命的估计不一致与照顾者感知到的肿瘤医生的自主性支持之间的关系。
Oncologist. 2021 Nov;26(11):e1992-e2001. doi: 10.1002/onco.13913. Epub 2021 Aug 11.
2
Postmastectomy Bolus: Urban Legend or Sound Practice?乳房切除术后大剂量注射:都市传说还是合理做法?
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1370-1372. doi: 10.1016/j.ijrobp.2021.04.024.
3
Development and validation of a ferroptosis-related prognostic model in pancreatic cancer.
中药诱导癌细胞程序性死亡的全球研究趋势:文献计量分析(1998 - 2024年)
Discov Oncol. 2025 Jun 21;16(1):1171. doi: 10.1007/s12672-025-02913-5.
4
A novel programmed cell death signature predicts clinical outcomes in clear cell renal cell carcinoma and identifies PLK1 as a therapeutic target.一种新型程序性细胞死亡特征可预测透明细胞肾细胞癌的临床结局,并将PLK1鉴定为治疗靶点。
Apoptosis. 2025 Jun 9. doi: 10.1007/s10495-025-02126-9.
5
A predictive model based on program cell death genes for prognosis and therapeutic response in early stage hepatocellular carcinoma.基于程序性细胞死亡基因的早期肝细胞癌预后及治疗反应预测模型。
Sci Rep. 2025 Apr 22;15(1):13937. doi: 10.1038/s41598-025-98634-4.
6
Role of ubiquitin-specific proteases in programmed cell death of breast cancer cells.泛素特异性蛋白酶在乳腺癌细胞程序性细胞死亡中的作用。
Genes Dis. 2024 Jun 3;12(3):101341. doi: 10.1016/j.gendis.2024.101341. eCollection 2025 May.
7
A gene signature related to programmed cell death to predict immunotherapy response and prognosis in colon adenocarcinoma.一种与程序性细胞死亡相关的基因特征,用于预测结肠腺癌的免疫治疗反应和预后。
PeerJ. 2025 Feb 10;13:e18895. doi: 10.7717/peerj.18895. eCollection 2025.
8
Copper in the colorectal cancer microenvironment: pioneering a new era of cuproptosis-based therapy.结直肠癌微环境中的铜:开创基于铜死亡疗法的新时代。
Front Oncol. 2025 Jan 9;14:1522919. doi: 10.3389/fonc.2024.1522919. eCollection 2024.
9
Cold Atmospheric Plasma: Possible Cure of Autoimmune Disorders and Cancer via Attenuating Inflammation.冷等离体技术:通过减轻炎症可能治愈自身免疫性疾病和癌症。
Int J Biol Sci. 2024 Oct 7;20(14):5436-5449. doi: 10.7150/ijbs.102445. eCollection 2024.
10
Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.肿瘤细胞耐药性休眠细胞的可塑性:提高抗癌疗法效果的革新策略。
Signal Transduct Target Ther. 2024 Aug 14;9(1):209. doi: 10.1038/s41392-024-01891-4.
开发和验证胰腺癌中与铁死亡相关的预后模型。
Invest New Drugs. 2021 Dec;39(6):1507-1522. doi: 10.1007/s10637-021-01114-5. Epub 2021 Jun 30.
4
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.曲妥珠单抗-美坦新偶联物与曲妥珠单抗联合紫杉醇用于 I 期 HER2 阳性乳腺癌(ATEMPT)的辅助治疗:一项随机临床试验。
J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2.
5
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival.多西他赛撤退治疗且无泼尼松用于仅接受多西他赛治疗时代的转移性去势抵抗性前列腺癌:对 PSA 动力学和生存的影响。
Adv Ther. 2021 Jul;38(7):3831-3841. doi: 10.1007/s12325-021-01778-8. Epub 2021 May 27.
6
Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.依维莫司治疗转移性乳腺癌的真实世界药代动力学和药效学。
Invest New Drugs. 2021 Dec;39(6):1707-1715. doi: 10.1007/s10637-021-01131-4. Epub 2021 May 26.
7
Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.西妥昔单抗联合顺铂与紫杉醇单独或联合治疗头颈部鳞状细胞癌患者的疗效和安全性:一项随机试验。
Cancer Control. 2021 Jan-Dec;28:1073274821997444. doi: 10.1177/1073274821997444.
8
Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer.桔梗皂苷D与索拉非尼联合对去势抵抗性及PTEN缺失型前列腺癌的抗癌作用
Front Oncol. 2021 May 7;11:648985. doi: 10.3389/fonc.2021.648985. eCollection 2021.
9
Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis.环状RNA circ_0006168通过调控miR-194-5p/JMJD1C轴增强食管鳞状细胞癌对紫杉醇的耐药性。
Cancer Cell Int. 2021 May 22;21(1):273. doi: 10.1186/s12935-021-01984-y.
10
Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial.S-1联合顺铂辅助化疗用于完全切除的非小细胞肺癌的可接受性和可行性:一项开放标签、单臂、多中心、2期试验。
J Thorac Dis. 2021 Apr;13(4):2224-2232. doi: 10.21037/jtd-20-3293.